Summit Therapeutics (SMMT) Hurt Bronte Capital. Here’s Why
Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here.
Summit Therapeutics Inc. (SMMT)
Market is closed
News
- 1 - 10
- Next >>
Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2024 Earnings Call Transcript
Operator: Good morning. And welcome to Summit Therapeutics' Q3 2024 Earnings and Update Call.
8 Unstoppable Stocks That Could Make You Richer
In the current climate of extreme market volatility, finding safe and stable investments is challenging.
10 Best QQQ Stocks to Buy According to Analysts
Several recent discussions have focused solely on the implications of the Fed's recent rate cut for the market.
10 Best Performing NASDAQ Stocks in 2024
Fed's recent cut has resulted in significant outperformance in the tech sector, signaling a positive sentiment among investors.
7 Best High Short Interest Stocks To Invest In
China's housing market, once a booming sector, has experienced a significant downturn in recent years.
10 Best Performing Stocks in 2024
The Dow Jones Industrial Average has recently made headlines by closing above the 42,000 mark for the first time, a significant milestone that reflects a surge in investor confidence following a substantial...
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript
Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06.
Insiders Are Buying These 11 Penny Stocks
US stock market started the second quarter of 2024 in the red, driven by rising treasury yields, broader volatility and uncertainty around rate cuts as inflation remains sticky.
Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call Transcript
Operator: Good morning and welcome to Summit's Fourth Quarter and Year End 2023 Earnings Call. [Operator Instructions] Please refer to the company's website for updates.
- 1 - 10
- Next >>
Billionaire Hedge Funds
